ReviewDrug design, development and therapy2021

Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.

Joanna M Rhodes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.